SHERWIN STEPHEN A 4

What Happened

• Stephen A. Sherwin, a director of Neurocrine Biosciences (NBIX), reported the exercise/conversion of 3,318 derivative units on 2026-05-21. The filing shows 3,318 shares "acquired" at $0.00 and a simultaneous reporting of 3,318 derivative units "disposed" at $0.00. This reflects conversion/settlement of RSUs (restricted stock units) rather than an open-market purchase or sale; no cash amount is recorded.

Key Details

• Transaction date: 2026-05-21; filing date: 2026-05-21 (appears timely).
• Reported amounts: 3,318 shares acquired at $0.00; 3,318 derivative units disposed at $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 explains each RSU equals one share on vesting; F2 states the RSU award was granted on May 21, 2025 and is fully vested.
• No 10b5-1 plan, sale, or cash proceeds are indicated in this filing.

Context

• This transaction represents conversion/settlement of vested RSUs into common stock (a non-market event) rather than a purchase or sale that signals directional trading by the insider. Retail investors should view RSU vesting events as routine compensation-related transactions unless accompanied by a market sale.